Clinical Trials › NCT05809986
Recruiting
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
Sponsored by Novartis Pharmaceuticals
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 174
Target enrollment
Nov 2023
Start date
Sep 2026
Expected completion
Interventions / Treatments
Ofatumumab
Conditions studied
Relapsing Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
